Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Clinical and Experimental Rheumatology|July 1, 2008
HCV infection: pathogenesis, clinical manifestations and therapyA Antonelli, C Ferri, M Galeazzi, et al.
Clinical and Experimental Rheumatology|January 29, 2005
Clinical manifestations of Behçet's disease in 137 Italian patients: results of a multicenter studyN Pipitone, L Boiardi, I Olivieri, et al.
Rheumatology (Oxford, England)|September 15, 2007
Lack of association of the -463 G/A myeloperoxidase promoter polymorphism with Behcet's disease in Italian patientsF Atzeni, L Boiardi, B Casali, et al.
Reumatismo|August 3, 2021
Accuracy of synovial fluid analysis compared to histology for the identification of calcium pyrophosphate crystals: an ancillary study of the OMERACT US Working Group - CPPD subgroupS Sirotti, M Gutierrez, C Pineda, et al.
Autoimmunity Reviews|August 4, 2010
From endothelial dysfunction to atherosclerosisS Sitia, L Tomasoni, F Atzeni, et al.
Annals of the Rheumatic Diseases|January 21, 2014
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness studyP Emery, J E Gottenberg, A Rubbert-Roth, et al.
Clinical Rheumatology|October 6, 2017
Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEAF Iannone, G Ferraccioli, L Sinigaglia, et al.
Annals of the Rheumatic Diseases|July 6, 2016
EULAR revised recommendations for the management of fibromyalgiaG J Macfarlane, C Kronisch, L E Dean, et al.
Reumatismo|January 22, 2011
Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritisM Fabris, L Quartuccio, S Lombardi, et al.
Reumatismo|July 21, 2009
Etiopathogenetic mechanisms of fibromyalgia syndromeS Stisi, M Cazzola, D Buskila, et al.
Pageof 12